Armstrong submits neurosurgical robot to the FDA
This article was originally published in Clinica
Neurosurgical robot maker Armstrong Healthcare has submitted to the FDA a 510(k) application for clearance to sell its PathFinder system in the US. The image-guided device, which is already CE-marked for sale in Europe, can allow surgeons to perform intracranial surgery more accurately, while reducing the duration and complexity of procedures. As well as its uses in procedures ranging from routine brain tumour biopsies to complex functional neurosurgery, the system may also have application in ground-breaking techniques such as gene therapy, claims the UK firm.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.